United States Biotechnology & Medical Research

Ambrx Biopharma Cayman Inc (AMAM)

Track

The most recent insider trading activity at Ambrx Biopharma Cayman Inc occurred on December 26, 2023. During the final quarter of 2023, the company saw a series of proposed sales by HOPU Reunion Co Ltd, an entity affiliated with a former director. Prior to these transactions, executives and institutional investors engaged in various buying and selling activities.
Ticker: AMAM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Ambrx Biopharma Cayman Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
HOPU Reunion Co Ltd Affiliated with former director Non-Executive Director
Transaction date
Proposed sale
Price
242.34
Quantity 55,814
Value US$182,526
HOPU Reunion Co Ltd Affiliated with former director Non-Executive Director
Transaction date
Proposed sale
Price
267.23
Quantity 89,428
Value US$4,281,326
HOPU Reunion Co Ltd Affiliated with former director Non-Executive Director
Transaction date
Proposed sale
Price
322.58
Quantity 94,164
Value US$4,530,851
HOPU Reunion Co Ltd Affiliated with former director Non-Executive Director
Transaction date
Proposed sale
Price
12.02
Quantity 1,000,000
Value US$12,020,000
HOPU Reunion Co Ltd Affiliated with former director Non-Executive Director
Transaction date
Proposed sale
Price
11.72
Quantity 600,000
Value US$7,032,000
3.3
O'Connor Daniel J. CEO
Transaction date
Proposed sale
Price
9.82
Quantity 50,012
Value US$491,168
Nelson Sonja Chief Financial Officer Officer
Transaction date
Planned sale
Price
9.82
Quantity 12,778 -8.9%
Value US$125,480
3.3
O'Connor Daniel J. President and CEO Executive Director
Transaction date
Planned sale
Price
9.82
Quantity 50,012 -12.7%
Value US$491,118
Nelson Sonja CFO
Transaction date
Proposed sale
Price
9.82
Quantity 12,778
Value US$125,493
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-12-26 2023-12-26 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
55,814
242.34
US$182,526 		55,814 242.34 US$182,526
2023-12-19 2023-12-19 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
89,428
267.23
US$4,281,326 		89,428 267.23 US$4,281,326
2023-12-08 2023-12-08 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
94,164
322.58
US$4,530,851 		94,164 322.58 US$4,530,851
2023-12-05 2023-12-05 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
1,000,000
12.02
US$12,020,000 		1,000,000 12.02 US$12,020,000
2023-12-01 2023-12-01 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
600,000
11.72
US$7,032,000 		600,000 11.72 US$7,032,000
2023-11-01 2023-10-27 PrS Proposed sale
3.3
O'Connor Daniel J.

CEO
50,012
9.82
US$491,168 		50,012 9.82 US$491,168
2023-10-31 2023-10-27 PlS Planned sale
Nelson Sonja

Chief Financial Officer

Officer
12,778 -8.9%
9.82
US$125,480 		12,778 -8.9% 9.82 US$125,480
2023-10-31 2023-10-27 PlS Planned sale
3.3
O'Connor Daniel J.

President and CEO

Executive Director
50,012 -12.7%
9.82
US$491,118 		50,012 -12.7% 9.82 US$491,118
2023-10-27 2023-10-27 PrS Proposed sale
Nelson Sonja

CFO
12,778
9.82
US$125,493 		12,778 9.82 US$125,493
2023-10-25 2023-10-23 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
1,307,311 +13.2%
6.99
US$9,139,542 		1,307,311 +13.2% 6.99 US$9,139,542
2023-09-19 2023-09-18 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
751,233 +1.1%
9.24
US$6,944,924 		751,233 +1.1% 9.24 US$6,944,924
2023-09-19 2023-09-15 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
1,401,505 +2.1%
9.05
US$12,680,677 		1,401,505 +2.1% 9.05 US$12,680,677
2023-04-20 2023-04-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
886,634 +1.3%
11.60
US$10,285,220 		886,634 +1.3% 11.60 US$10,285,220
2023-04-20 2023-04-19 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
951,909 +1.5%
11.15
US$10,612,357 		951,909 +1.5% 11.15 US$10,612,357
2023-04-20 2023-04-18 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
3,376,646 +5.4%
11.27
US$38,053,112 		3,376,646 +5.4% 11.27 US$38,053,112
2023-04-17 2023-04-17 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
562,121 +0.9%
10.67
US$5,999,461 		562,121 +0.9% 10.67 US$5,999,461
2023-04-17 2023-04-14 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
841,967 +1.4%
9.96
US$8,384,307 		841,967 +1.4% 9.96 US$8,384,307
2023-04-17 2023-04-13 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
1,193,808 +2.0%
9.16
US$10,935,520 		1,193,808 +2.0% 9.16 US$10,935,520
2023-03-16 2023-03-16 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
500,000 +0.9%
10.15
US$5,074,250 		500,000 +0.9% 10.15 US$5,074,250
2023-03-16 2023-03-15 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
250,000 +0.5%
10.60
US$2,648,875 		250,000 +0.5% 10.60 US$2,648,875
2023-03-16 2023-03-14 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
250,000 +0.5%
9.95
US$2,488,275 		250,000 +0.5% 9.95 US$2,488,275
Explore more

More insider trading research around Ambrx Biopharma Cayman Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America